biotech · Acute Respiratory Distress Syndrome (ARDS) · Allergic Contact Dermatitis · EDSA
Edesa Biotech
Edesa Biotech is a biotech organization headquartered in Markham, CA. It trades on NYSE under ticker EDSA. Primary therapeutic focus areas include Acute Respiratory Distress Syndrome (ARDS), Allergic Contact Dermatitis,
Markham, CA HQ
2015 Founded
22 Employees
Public company Type
EDSA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Markham, CA
- Founded
- 2015
- Employees
- 22
- Programs
- 5
- Drugs
- 5
- Patents
- 0
SOC plus 15mg/kg EB05 IV
Phase 3 · mab · COVID-19
SOC plus 15mg/kg EB05 IV for COVID-19 is a Phase 3 program (mab) at Edesa Biotech with 1 ClinicalTrials.gov record(s).
Internal code EB05-04-2020
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Edesa Biotech
- Phase
- Phase 3
- Modality
- mab
- Indication
- COVID-19
- Status
- on_hold
- Trials
- 1